Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;18(9):1687-1693.
doi: 10.1002/alz.12618. Epub 2022 Feb 25.

Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature

Henrik Zetterberg  1   2   3   4   5
Affiliations
Review

Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature

Henrik Zetterberg. Alzheimers Dement. 2022 Sep.

Abstract

The past few years have seen an explosion in sensitive and specific assays for cerebrospinal fluid (CSF) and blood biomarkers for Alzheimer's disease (AD) and related disorders, as well as some novel assays based on pathological seed-induced protein misfolding in patient samples. Here, I review this exciting field that promises to transform dementia diagnostics and disease monitoring. I discuss data on biomarkers for amyloid beta (Aβ) and tau pathology, neurodegeneration, and glial activation, mention the most promising biomarkers for α-synuclein and TDP-43 pathology, and highlight the need for further research into common co-pathologies. Finally, I consider practical aspects of blood-based biomarker-supported AD diagnostics and emphasize the importance of biomarker interpretation in a full clinical context.

Keywords: Alzheimer's disease; TDP-43; amyloid; biomarkers; blood; cerebrospinal fluid; glial fibrillary acidic protein; neurofilament light; plasma; synuclein; tau.

PubMed Disclaimer

Conflict of interest statement

Henrik Zetterberg has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).

References

    1. Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562. - PMC - PubMed
    1. Camporesi E, Nilsson J, Brinkmalm A, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15: 1177271920950319. - PMC - PubMed
    1. Mecca AP. AD molecular: molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems. Prog Mol Biol Transl Sci. 2019;165: 139‐165. - PubMed
    1. Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease‐preparing for a new era of disease‐modifying therapies. Mol Psychiatry. 2021;26(1):296‐308. - PMC - PubMed
    1. Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid‐neuropathology in a population‐based autopsy study. Neurology. 2003;60(4):652‐656. - PubMed

Publication types

MeSH terms